{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T21:01:23Z","timestamp":1777150883980,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.phrs.2012.02.008","type":"journal-article","created":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T19:27:58Z","timestamp":1330975678000},"page":"514-522","source":"Crossref","is-referenced-by-count":42,"title":["Differential susceptibility to the PPAR-\u03b3 agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease"],"prefix":"10.1016","volume":"65","author":[{"given":"C.","family":"Laloux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Petrault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lecointe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Devos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bordet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Pt 6","key":"10.1016\/j.phrs.2012.02.008_bib0005","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1042\/BST0341341","article-title":"PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases","volume":"34","author":"Bordet","year":"2006","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.phrs.2012.02.008_bib0010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu Rev Med"},{"issue":"5","key":"10.1016\/j.phrs.2012.02.008_bib0015","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1210\/er.20.5.649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.phrs.2012.02.008_bib0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1677\/joe.0.1690453","article-title":"Peroxisome proliferator-activated receptors in inflammation control","volume":"169","author":"Delerive","year":"2001","journal-title":"J Endocrinol"},{"key":"10.1016\/j.phrs.2012.02.008_bib0025","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2741\/2802","article-title":"Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists","volume":"13","author":"Kapadia","year":"2008","journal-title":"Front Biosci"},{"issue":"4","key":"10.1016\/j.phrs.2012.02.008_bib0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1358\/dnp.2010.23.4.1437710","article-title":"Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents","volume":"23","author":"Kaundal","year":"2010","journal-title":"Drug News Perspect"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neuint.2006.03.020","article-title":"PPARgamma as a therapeutic target in central nervous system diseases","volume":"49","author":"Sundararajan","year":"2006","journal-title":"Neurochem Int"},{"issue":"3","key":"10.1016\/j.phrs.2012.02.008_bib0040","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1189\/jlb.0803402","article-title":"Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients","volume":"75","author":"Schmidt","year":"2004","journal-title":"J Leukoc Biol"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/01.STR.0000152271.21943.a2","article-title":"A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia","volume":"36","author":"Shimazu","year":"2005","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.phrs.2012.02.008_bib0050","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1096\/fj.05-5007com","article-title":"Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats","volume":"20","author":"Zhao","year":"2006","journal-title":"FASEB J"},{"issue":"3","key":"10.1016\/j.phrs.2012.02.008_bib0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1753944708090924","article-title":"PPARs as new therapeutic targets for the treatment of cerebral ischemia\/reperfusion injury","volume":"2","author":"Collino","year":"2008","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"2\u20133","key":"10.1016\/j.phrs.2012.02.008_bib0060","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12035-010-8103-y","article-title":"Anti-apoptotic actions of PPAR-gamma against ischemic stroke","volume":"41","author":"Fong","year":"2010","journal-title":"Mol Neurobiol"},{"issue":"3","key":"10.1016\/j.phrs.2012.02.008_bib0065","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nurt.2008.05.003","article-title":"PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease","volume":"5","author":"Landreth","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.phrs.2012.02.008_bib0070","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.pharmthera.2005.08.007","article-title":"Peroxisome proliferator-activated receptors and inflammation","volume":"110","author":"Moraes","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.phrs.2012.02.008_bib0075","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1471-4159.2002.00990.x","article-title":"Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease","volume":"82","author":"Breidert","year":"2002","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0080","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1471-4159.2003.02210.x","article-title":"Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation","volume":"88","author":"Dehmer","year":"2004","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.phrs.2012.02.008_bib0085","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/bjp.2008.78","article-title":"The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B","volume":"154","author":"Quinn","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2012.02.008_bib0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1742-2094-8-91","article-title":"The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys","volume":"8","author":"Swanson","year":"2011","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.phrs.2012.02.008_bib0095","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbr.2010.07.033","article-title":"Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease","volume":"216","author":"Barbiero","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.phrs.2012.02.008_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2011.05.001","article-title":"Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease","author":"Ulusoy","year":"2011","journal-title":"Brain Res Bull"},{"issue":"3","key":"10.1016\/j.phrs.2012.02.008_bib0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/FBP.0b013e32833a5c81","article-title":"Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease","volume":"21","author":"Kreisler","year":"2010","journal-title":"Behav Pharmacol"},{"issue":"4","key":"10.1016\/j.phrs.2012.02.008_bib0110","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0306-4522(83)90008-8","article-title":"Effects of unilateral electrical stimulation of various thalamic nuclei on the release of dopamine from dendrites and nerve terminals of neurons of the two nigrostriatal dopaminergic pathways","volume":"8","author":"Cheramy","year":"1983","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0006-8993(86)91525-8","article-title":"Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"399","author":"Sirinathsinghji","year":"1986","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/j.phrs.2012.02.008_bib0120","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/syn.890210404","article-title":"Interhemispheric modulation of dopamine receptor interactions in unilateral 6-OHDA rodent model","volume":"21","author":"Lawler","year":"1995","journal-title":"Synapse"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0125","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/cne.1098","article-title":"Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways","volume":"432","author":"Roedter","year":"2001","journal-title":"J Comp Neurol"},{"issue":"6","key":"10.1016\/j.phrs.2012.02.008_bib0130","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/j.1471-4159.2010.06682.x","article-title":"Pre-synaptic glutamate-induced activation of DA release in the striatum after partial nigral lesion","volume":"113","author":"Dzahini","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.phrs.2012.02.008_bib0135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-201X.1971.tb11001.x","article-title":"Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system","volume":"367","author":"Ungerstedt","year":"1971","journal-title":"Acta Physiol Scand Suppl"},{"issue":"7","key":"10.1016\/j.phrs.2012.02.008_bib0140","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nrn877","article-title":"Animal models of neurological deficits: how relevant is the rat?","volume":"3","author":"Cenci","year":"2002","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.phrs.2012.02.008_bib0145","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"1986"},{"issue":"7","key":"10.1016\/j.phrs.2012.02.008_bib0150","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1073\/pnas.94.7.3363","article-title":"Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa","volume":"94","author":"Bordet","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.phrs.2012.02.008_bib0155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0091-3057(78)90131-4","article-title":"A simple recording grip strength device","volume":"8","author":"Cabe","year":"1978","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"10.1016\/j.phrs.2012.02.008_bib0160","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0306-4522(01)00295-0","article-title":"Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP\/probenecid treatment","volume":"106","author":"Petroske","year":"2001","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.phrs.2012.02.008_bib0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.brainres.2006.12.011","article-title":"Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not","volume":"1135","author":"Kreisler","year":"2007","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.phrs.2012.02.008_bib0170","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1460-9568.2009.06657.x","article-title":"PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease","volume":"29","author":"Schintu","year":"2009","journal-title":"Eur J Neurosci"},{"issue":"5","key":"10.1016\/j.phrs.2012.02.008_bib0175","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1471-4159.2006.04327.x","article-title":"Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system","volume":"100","author":"Hunter","year":"2007","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.phrs.2012.02.008_bib0180","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neulet.2007.12.019","article-title":"Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats","volume":"432","author":"Hunter","year":"2008","journal-title":"Neurosci Lett"},{"issue":"7","key":"10.1016\/j.phrs.2012.02.008_bib0185","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2990.2010.01107.x","article-title":"Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system","volume":"36","author":"Yu","year":"2010","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1\u20132","key":"10.1016\/j.phrs.2012.02.008_bib0190","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2007.09.029","article-title":"Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity","volume":"192","author":"Xing","year":"2007","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.phrs.2012.02.008_bib0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbrc.2005.11.177","article-title":"Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity","volume":"340","author":"Jung","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"1\u20132","key":"10.1016\/j.phrs.2012.02.008_bib0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2006.11.020","article-title":"Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production","volume":"253","author":"Jung","year":"2007","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0205","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/14740331003623218","article-title":"Pioglitazone: side effect and safety profile","volume":"9","author":"Shah","year":"2010","journal-title":"Expert Opin Drug Safety"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0210","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.expneurol.2004.03.005","article-title":"Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease","volume":"187","author":"Blandini","year":"2004","journal-title":"Exp Neurol"},{"issue":"5","key":"10.1016\/j.phrs.2012.02.008_bib0215","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s004010050453","article-title":"Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity","volume":"91","author":"Salonen","year":"1996","journal-title":"Acta Neuropathol"},{"issue":"18","key":"10.1016\/j.phrs.2012.02.008_bib0220","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1523\/JNEUROSCI.20-18-06862.2000","article-title":"Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo","volume":"20","author":"Heneka","year":"2000","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0225","first-page":"278","article-title":"Anti-inflammatory effect of PPARgamma agonists: basics and clinical applications","volume":"68","author":"Wada","year":"2010","journal-title":"Nihon Rinsho"},{"issue":"4","key":"10.1016\/j.phrs.2012.02.008_bib0230","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coph.2006.03.012","article-title":"PPARs and other nuclear receptors in inflammation","volume":"6","author":"Rizzo","year":"2006","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0235","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.arr.2008.01.001","article-title":"Molecular mechanism of PPAR in the regulation of age-related inflammation","volume":"7","author":"Chung","year":"2008","journal-title":"Ageing Res Rev"},{"issue":"4","key":"10.1016\/j.phrs.2012.02.008_bib0240","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1046\/j.1471-4159.1995.64041703.x","article-title":"Free radical-generated neurotoxicity of 6-hydroxydopamine","volume":"64","author":"Kumar","year":"1995","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0245","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","article-title":"Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease","volume":"65","author":"Blum","year":"2001","journal-title":"Prog Neurobiol"},{"issue":"3","key":"10.1016\/j.phrs.2012.02.008_bib0250","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1602\/neurorx.2.3.484","article-title":"Toxin-induced models of Parkinson's disease","volume":"2","author":"Bove","year":"2005","journal-title":"NeuroRx"},{"issue":"5","key":"10.1016\/j.phrs.2012.02.008_bib0255","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10072-008-0986-2","article-title":"Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease","volume":"29","author":"Yokoyama","year":"2008","journal-title":"Neurol Sci"},{"issue":"11","key":"10.1016\/j.phrs.2012.02.008_bib0260","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s007020100004","article-title":"Neurochemical findings in the MPTP model of Parkinson's disease","volume":"108","author":"Schmidt","year":"2001","journal-title":"J Neural Transm"},{"issue":"6662","key":"10.1016\/j.phrs.2012.02.008_bib0265","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/34184","article-title":"PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines","volume":"391","author":"Jiang","year":"1998","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.phrs.2012.02.008_bib0270","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0304-3940(94)90684-X","article-title":"Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease","volume":"172","author":"Boka","year":"1994","journal-title":"Neurosci Lett"},{"issue":"6662","key":"10.1016\/j.phrs.2012.02.008_bib0275","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0280","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1523\/JNEUROSCI.20-02-00558.2000","article-title":"Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists","volume":"20","author":"Combs","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.phrs.2012.02.008_bib0285","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neuroscience.2011.07.046","article-title":"Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model","volume":"194","author":"Carta","year":"2011","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0290","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/exnr.1998.6848","article-title":"Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat","volume":"152","author":"Kirik","year":"1998","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.phrs.2012.02.008_bib0295","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jneumeth.2004.10.004","article-title":"Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease","volume":"144","author":"Yuan","year":"2005","journal-title":"J Neurosci Methods"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0300","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0306-4522(94)90605-X","article-title":"Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat","volume":"59","author":"Sauer","year":"1994","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.phrs.2012.02.008_bib0305","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1460-9568.1995.tb01085.x","article-title":"Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat","volume":"7","author":"Amalric","year":"1995","journal-title":"Eur J Neurosci"},{"issue":"1\u20132","key":"10.1016\/j.phrs.2012.02.008_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-4328(98)00160-0","article-title":"Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats","volume":"102","author":"Lindner","year":"1999","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.1016\/j.phrs.2012.02.008_bib0315","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1471-4159.2008.05388.x","article-title":"PPAR: a therapeutic target in Parkinson's disease","volume":"106","author":"Chaturvedi","year":"2008","journal-title":"J Neurochem"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661812000321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661812000321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T00:50:46Z","timestamp":1713660646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661812000321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1043661812000321"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2012.02.008","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}